{
    "organizations": [],
    "uuid": "b01eaef3adf65645275ccbaed823a23d47254337",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-incyte-corp-co-syros-pharmaceutica/brief-incyte-corp-co-syros-pharmaceuticals-have-entered-into-target-discovery-research-collaboration-and-option-agreement-idUSFWN1P30Q1",
    "ord_in_thread": 0,
    "title": "BRIEF-Incyte Corp - Co, Syros Pharmaceuticals Have Entered Into Target Discovery, Research Collaboration And Option Agreement",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Jan 8 (Reuters) - Incyte Corp:\n* INCYTE CORP - CO, SYROS PHARMACEUTICALS HAVE ENTERED INTO A TARGET DISCOVERY, RESEARCH COLLABORATION AND OPTION AGREEMENT\n* INCYTE-‍UNDER AGREEMENT, SYROS TO USE ITS GENE CONTROL PLATFORM TO IDENTIFY NOVEL THERAPEUTIC TARGETS WITH FOCUS IN MYELOPROLIFERATIVE NEOPLASMS​\n* INCYTE - CO TO HAVE EXCLUSIVE WORLDWIDE RIGHTS TO DEVELOP AND COMMERCIALIZE ANY THERAPIES UNDER COLLABORATION THAT MODULATE VALIDATED TARGETS​\n* INCYTE - UNDER DEAL, CO TO GET OPTIONS TO GET EXCLUSIVE WORLDWIDE RIGHTS TO INTELLECTUAL PROPERTY FROM COLLABORATION FOR UP TO SEVEN VALIDATED TARGETS\n* INCYTE CORP - ‍ UNDER TERMS , CO TO PAY SYROS $10 MILLION UPFRONT AND PURCHASE A TOTAL OF $10 MILLION IN SYROS COMMON STOCK AT $12.61 PER SHARE​\n* INCYTE - SHOULD INCYTE EXERCISE ALL OF ITS OPTIONS UNDER DEAL, SYROS COULD GET UP TO $54 MILLION FROM INCYTE IN TARGET SELECTION & OPTION EXERCISE FEES\n* INCYTE CORP - SYROS COULD ALSO RECEIVE UP TO $50 MILLION IN DEVELOPMENT AND REGULATORY MILESTONES, AS WELL AS UP TO $65 MILLION IN COMMERCIAL MILESTONES\n* INCYTE CORP - SYROS WOULD ALSO BE ELIGIBLE TO RECEIVE LOW SINGLE-DIGIT ROYALTIES ON SALES OF PRODUCTS RESULTING FROM COLLABORATION Source text for Eikon: Further company coverage:\n ",
    "published": "2018-01-08T21:20:00.000+02:00",
    "crawled": "2018-01-09T17:17:53.020+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "jan",
        "reuters",
        "incyte",
        "corp",
        "incyte",
        "corp",
        "co",
        "syros",
        "pharmaceutical",
        "entered",
        "target",
        "discovery",
        "research",
        "collaboration",
        "option",
        "agreement",
        "agreement",
        "syros",
        "use",
        "gene",
        "control",
        "platform",
        "identify",
        "novel",
        "therapeutic",
        "target",
        "focus",
        "myeloproliferative",
        "incyte",
        "co",
        "exclusive",
        "worldwide",
        "right",
        "develop",
        "commercialize",
        "therapy",
        "collaboration",
        "modulate",
        "validated",
        "incyte",
        "deal",
        "co",
        "get",
        "option",
        "get",
        "exclusive",
        "worldwide",
        "right",
        "intellectual",
        "property",
        "collaboration",
        "seven",
        "validated",
        "target",
        "incyte",
        "corp",
        "term",
        "co",
        "pay",
        "syros",
        "million",
        "upfront",
        "purchase",
        "total",
        "million",
        "syros",
        "common",
        "stock",
        "per",
        "incyte",
        "incyte",
        "exercise",
        "option",
        "deal",
        "syros",
        "could",
        "get",
        "million",
        "incyte",
        "target",
        "selection",
        "option",
        "exercise",
        "fee",
        "incyte",
        "corp",
        "syros",
        "could",
        "also",
        "receive",
        "million",
        "development",
        "regulatory",
        "milestone",
        "well",
        "million",
        "commercial",
        "milestone",
        "incyte",
        "corp",
        "syros",
        "would",
        "also",
        "eligible",
        "receive",
        "low",
        "royalty",
        "sale",
        "product",
        "resulting",
        "collaboration",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}